Physician profile
Emmanuelle Hebert
NPI 1922540129
$462.69
in general payments reported to CMS, 2019-2025
12 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $19.40 · 2023: $89.62 · 2024: $197 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $443.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $110.64 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $53.36 | 2024-2025 | |
| Revance Therapeutics, INC. | $50.10 | 2025 | Daxxify |
| Exact Sciences Corporation | $47.56 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $47.36 | 2023-2024 | |
| Lilly USA, LLC | $28.69 | 2023-2024 | Mounjaro |
| Novo Nordisk INC | $26.30 | 2023 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $24.30 | 2024 | Repatha, Otezla |
| Sanofi Pasteur INC. | $21.57 | 2024 | |
| Astellas Pharma US INC | $19.17 | 2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $17.11 | 2024 | Airsupra |
| Merck Sharp & Dohme LLC | $16.53 | 2023 | Gardasil 9, Vaxneuvance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmanuelle Hebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.